Saturna Capital Corp Purchases 171 Shares of Stryker Co. (NYSE:SYK)

Saturna Capital Corp grew its position in Stryker Co. (NYSE:SYK) by 0.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 313,441 shares of the medical technology company’s stock after purchasing an additional 171 shares during the quarter. Stryker accounts for approximately 1.5% of Saturna Capital Corp’s investment portfolio, making the stock its 25th biggest holding. Saturna Capital Corp’s holdings in Stryker were worth $112,854,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Chicago Capital LLC lifted its position in Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock valued at $70,228,000 after acquiring an additional 5,841 shares in the last quarter. Zhang Financial LLC raised its position in Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after buying an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA lifted its stake in Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock valued at $10,521,000 after acquiring an additional 1,400 shares during the period. Metis Global Partners LLC boosted its holdings in shares of Stryker by 10.2% during the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock valued at $6,064,000 after acquiring an additional 1,561 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock worth $65,829,000 after acquiring an additional 976 shares during the period. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. increased their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. Finally, Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Trading Down 1.3 %

Shares of Stryker stock opened at $365.35 on Wednesday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company has a market capitalization of $139.41 billion, a P/E ratio of 47.08, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a fifty day moving average of $382.70 and a 200 day moving average of $373.40.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business earned $3.46 earnings per share. On average, sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Transactions at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.